上海联影医疗科技股份有限公司董事会薪酬与考核委员会 关于公司 2025 年限制性股票激励计划 （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 2、本激励计划首次授予的激励对象符合《公司法》《证券法》等法律、法 规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规 则》等法律、法规和规范性文件规定的激励对象条件，其作为公司本激励计划 激励对象的主体资格合法、有效。 首次授予激励对象名单（首次授予日）的核查意见 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开第二届董事会 2025 年第三次会议，审议通过了《关于向公司 2025 年限制 性股票激励计划激励对象首次授予限制性股票的议案》。 公司董事会薪酬与考核委员会依据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股权激励管理办法》（以下简 ...

一、董事会会议召开情况 上海联影医疗科技股份有限公司（以下简称"公司"）第二届董事会第二十 二次会议于 2025 年 8 月 25 日在公司会议室召开，会议同时采用了现场与通讯相 结合的表决方式，经公司全体董事书面同意，本次董事会临时会议豁免提前 5 日的通知时限，会议通知于 2025 年 8 月 25 日送达公司全体董事。本次会议由全 体董事推举张强先生主持，会议应参加表决董事 9 人，实际参加表决董事 9 人。 本次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 等法律法规以及《上海联影医疗科技股份有限公司章程》（以下简称"《公司章 程》"）的相关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于调整公司 2025 年限制性股票激励计划首次授予价格 的议案》 证券代码：688271 证券简称：联影医疗 公告编号：2025-033 上海联影医疗科技股份有限公司 第二届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本议案经董事会薪酬与考核委员会审 ...

一、停复牌 东珠生态：筹划收购凯睿星通控股权，股票停牌。 二、并购重组 2、工大科雅：拟以3000万元-5000万元回购股份。 四、投资合作、经营状况 五、业绩变动 1、必易微：拟以2.95亿元现金收购上海兴感半导体100%股权。通过整合双方资源，预计将形成涵盖电 流检测、运动感知、电源管理、电池管理、电机驱动的完整产品体系，提升技术领先地位和产品竞争 力。 2、南新制药：拟现金收购未来医药持有的标的资产组，预计构成重大资产重组。 3、中国石油：拟400亿元人民币收购储气库企业。 三、回购 1、长盈精密：拟以5000万元-1亿元回购股份。 1、鹏鼎控股：服务器及光模块等产品已通过部分客户的认证。 2、世运电路：拟投资建设"芯创智载"新一代PCB智造基地项目，投资金额15亿元。 3、泛亚微透：拟定增募资不超过6.99亿元，用于6G通讯的低介电损耗FCCL挠性覆铜板产业化项目等。 4、奥普特：目前东莞泰莱机器人关节模组产品已在送样过程中。 5、联影医疗：自研的中国首款光子计数能谱CT取得医疗器械注册证。 6、金龙机电：全资子公司兴科电子烟草专卖生产企业许可证续期。 7、海南发展：控股子公司中标约3.65亿元迪拜岛 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight increase, with a closing price of 136.5 yuan on August 26, 2025, reflecting a 0.48% rise, amidst varied capital flows from different investor groups [1][2]. Group 1: Stock Performance and Capital Flow - On August 26, 2025, the stock recorded a trading volume of 61,800 hands and a total transaction value of 845 million yuan [1]. - The net inflow of main funds was 15.54 million yuan, accounting for 1.84% of the total transaction value, while retail investors experienced a net outflow of 13.82 million yuan, representing 1.63% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on multiple days [2]. Group 2: Financial Metrics and Industry Ranking - United Imaging Healthcare has a total market capitalization of 112.498 billion yuan, ranking second in the medical device industry [3]. - The company reported a net profit of 370 million yuan for the first quarter of 2025, reflecting a year-on-year increase of 1.87%, with a gross margin of 49.94% [3]. - The company's price-to-earnings ratio (P/E) stands at 75.99, which is higher than the industry average of 66.21, indicating a premium valuation compared to peers [3]. Group 3: Analyst Ratings - In the last 90 days, 17 institutions have provided ratings for the stock, with 12 recommending a buy and 5 suggesting an increase in holdings [4]. - The average target price set by institutions over the past 90 days is 149.48 yuan, indicating potential upside from the current trading price [4].

Group 1 - The Shanghai Science and Technology Awards 2024 recognized a total of 206 awards, including various categories such as the Shanghai Science and Technology Progress Award and the Shanghai International Science and Technology Cooperation Award [1] - Among the award recipients, 1,171 individuals under the age of 45 accounted for 65% of the total, indicating a growing recognition of young scientists in Shanghai's innovation landscape [2] - The number of enterprises involved in award-winning projects reached 336, representing 49% of all completion units, with a notable increase in participation from private enterprises [3] Group 2 - The focus on technology transfer and industrial application is emphasized, with 34 projects directly mentioning "application," making up 54% of high-level award-winning results [4] - The Shanghai government is actively promoting the construction of an international technology innovation center, supporting both state-owned and private enterprises in innovation and development [5] - The success of young scientists and enterprises is seen as a vital source of innovation for Shanghai's technological ecosystem [6]

Core Insights - The company announced on August 26 that it received the Medical Device Registration Certificate for its photon-counting spectral CT from the National Medical Products Administration on August 25, 2025 [1] - This product is the first photon-counting spectral CT independently developed in China, marking a significant breakthrough in the medical technology field [1] - The company becomes the first Chinese enterprise to successfully commercialize photon-counting spectral CT globally [1]

格隆汇8月26日｜联影医疗(688271.SH)公告称，公司于2025年8月25日收到国家药品监督管理局颁发的 光子计数能谱CT《医疗器械注册证》。该产品为公司自主研发的中国首款光子计数能谱CT，标志着我 国在医疗科技领域的又一重大突破。公司成为全球首家成功实现光子计数能谱CT商业化的中国企业。 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2025-032 上海联影医疗科技股份有限公司关于取得光子计数能谱 CT 医疗器械注册证的自愿性信息披露公告 截至本公告披露日，公司全球注册覆盖超 80 个国家和地区，产品累计获批 上市数量超过 140 款，其中包括 53 项产品获得 FDA 510(k)认证、57 款产品获得 | 类别 | 产品名称 | 生效日期 | 有效期至 | | --- | --- | --- | --- | | NMPA X | 射线计算机体层摄影设备 | 2025/08/25 | 2030/08/24 | 特此公告。 本次获得《医疗器械注册证》的光子计数能谱 CT，是由公司自主研发的中 国首款光子计数能谱 CT uCT Ultima，这是我国在医疗科技领域实现的又一重大 突破，也是我国"十四五"国家重点研发计划重点专项"光子计数能谱 CT 研发" 项目取得的重大进展。至此，公司成为全球范围内，首家成功实现光子计数能谱 CT 商业化的中国企业。 光子计数能谱 CT 一直是备受行业关注的下一代 CT 技术的革命方向。相比于 传统 CT，光子计数能谱 CT 搭载了半导体探测器， ...

联影医疗公告，公司于2025年8月25日收到国家药品监督管理局颁发的关于光子计数能谱CT的《医疗器 械注册证》。该注册证的有效期至2030年8月24日。此次获得注册证的产品是公司自主研发的中国首款 光子计数能谱CT uCT Ultima，这标志着公司在医疗科技领域取得重大突破，成为全球首家成功实现光 子计数能谱CT商业化的中国企业。 ...

Core Insights - NVIDIA has launched Jetson Thor, a next-generation supercomputer for robotics, which significantly enhances AI computing power and energy efficiency compared to its predecessor, Jetson Orin [2][3] - Jetson Thor offers 7.5 times the AI computing power and 3.5 times the energy efficiency, supporting various generative AI models and specialized robotics models [2][4] - The product is priced at $3,499 for the developer kit and $2,999 per unit for bulk purchases of the Jetson T5000 module, with several leading robotics companies already adopting it [2][4] Group 1: Product Features and Capabilities - Jetson Thor integrates "large models + real-time sensing + control" at the edge, providing up to 2070 FP4 TFLOPS of AI computing power [3][5] - The platform allows for parallel execution of multimodal models, reducing reliance on cloud computing and latency [3][5] - It supports a wide range of robotic applications, including humanoid robots, surgical assistance robots, and industrial robotic arms, enhancing real-time inference capabilities [4][6] Group 2: Strategic Positioning and Market Impact - NVIDIA positions itself as a supporter of the robotics ecosystem rather than a manufacturer, focusing on providing a comprehensive hardware and software platform [3][4] - The introduction of Jetson Thor is seen as a critical step in advancing "Physical AI," which aims to enable robots to perform complex tasks in real-world environments [5][6] - Market analysts view Jetson Thor as a potential new growth curve for NVIDIA, with the robotics sector expected to have long-term potential despite current challenges [6][7]